ReviewSignal transduction and targeted therapy2026
The histone deacetylase family in health and disease.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Zinc-dependent classical histone deacetylases, including Classes I, II, and IV, are ubiquitously present in mammals and play vital roles in numerous biological processes. To date, eleven histone deacetylase members have been identified, namely, histone deacetylase 1 through histone deacetylase 11. A growing body of evidence underscores the crucial roles of these histone deacetylase members in both physiological and pathological conditions. Notably, these histone deacetylase members are involved in various cellular processes, including inflammation, metabolism, apoptosis, and oxidative stress. Consequently, histone deacetylases have emerged as promising therapeutic targets for a range of pathological conditions, including tumors, cardiovascular diseases, and neurological disorders. Moreover, the development of histone deacetylase modulators, which can regulate their activity, has shown significant therapeutic potential across various conditions. Several histone deacetylase inhibitors have been approved by the U.S. Food and Drug Administration for the treatment of multiple tumors and Duchenne muscular dystrophy, while many others are being developed for oncology and other therapeutic applications. In this review, we introduce the research history and structural characteristics of histone deacetylases. We then summarize the molecular mechanisms and biological functions of the eleven histone deacetylase family members. Moreover, we elucidate the critical regulatory roles of histone deacetylases in various human diseases. Furthermore, we provide an overview of histone deacetylase modulators, their current clinical applications, and potential benefits, offering insight into the regulation of histone deacetylases for the treatment of related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.